Evidence map›Paper›PMID 41471299›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Emodin Enhances Rosiglitazone's Therapeutic Profile by Dual Modulation of SREBP1-Mediated Adipogenesis and PPARγ-Driven Thermogenesis.

Meng Li, Yi-Rong Wang, Xue Wang, Xiao-Li Xiao, Yun-Hong Sun, Sheng-An Zhang, Yan-Qi Dang, Kai Wang, Wen-Jun Zhou

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Meng LiInstitute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.ORCID 0000-0002-3602-3429
Yi-Rong WangInstitute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Xue WangInstitute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Xiao-Li XiaoInstitute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Yun-Hong SunInstitute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.ORCID 0009-0000-7050-8940
Sheng-An ZhangInstitute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Yan-Qi DangInstitute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.ORCID 0000-0002-0316-7880
Kai WangExperiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Wen-Jun ZhouInstitute of Digestive Diseases, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.

Funding

National Natural Science Foundation of China 81803897National Natural Science Foundation of China 82104479State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine LSLSKL20240128State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine LSLSKL20240130
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adipogenesisemodininsulin sensitivityobesityPPARγrosiglitazonethermogenesistype 2 diabetes

Identifiers

PMID41471299
PMCPMC12736021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.